The HIV vaccine research study enrolls its first participants in international trial using mRNA technology developed for the COVID-19 vaccine
NEW YORK CITY – New York Blood Center’s Project ACHIEVE and Columbia University’s Columbia Research Unit are working in partnership for the New York City effort to advance the use of messenger ribonucleic acid (mRNA) technology in an HIV preventive vaccine study – HVTN 302. The global research effort is sponsored by the National Institute of Health (NIH) – funded HIV Vaccine Trials Network (HVTN), headquartered at the Fred Hutchinson Cancer Research Center in Seattle, WA.
The Phase 1 trial, titled HVTN 302, is the second trial of its kind and will be enrolling up to 108 people across 10 sites in the United States to test 3 different experimental vaccines against HIV using the mRNA vaccine technology that has been successful in fighting COVID-19. The vaccines are experimental, meaning that they have not been approved by the U.S. Food and Drug Administration (FDA). Researchers will study the safety of and immune responses to the different vaccines, focusing on which might be the best vaccine candidate as well as what might be the best dosage.
Both organizations have an extensive history of conducting research spanning all phases of HIV prevention clinical research. They have conducted longstanding work in community engagement and recruitment throughout New York City, developing a reputation for enrolling a diverse pool of study participants and addressing mistrust in vaccine trials among racial, ethnic, and sexual minority communities.
“Seeing the first participant in HVTN 302 receive their initial injection of the study vaccine at our clinic site provides me hope that we can make a major contribution to the scientific community’s goal to prevent the spread of HIV. Globally more than thirty-seven million people are living with HIV. There have been major advances in HIV prevention, care, and treatment, but a vaccine will impact the broadest segment of society. We’re looking forward to applying what we learned from the COVID-19 vaccine trials to our research on this potentially groundbreaking vaccine,” stated Hong Van Tieu, MD, MS, Head, Laboratory of Infectious Disease Prevention, LFKRI, New York Blood Center’s Project ACHIEVE.
“We are immensely honored and excited to be working on this significant advancement in HIV vaccine research. We have been studying various HIV vaccine products for decades and the science continues to progress. The major advancements in COVID-19 vaccine development involved the use of the mRNA technology. Applying this technology to HIV vaccine research is a major turning point. Community members in New York City continue to enroll in this study which will help further the global effort to develop an HIV preventive vaccine,” stated Magda Sobieszczyk, MD, MPH, Principal Investigator, Columbia University’s Columbia Research Unit.
The HVTN 302 trial is evaluating three experimental vaccines; each participant in the trial will get one of the vaccines, all of which use mRNA technology. The International AIDS Vaccine Initiative (IAVI) on behalf of Scripps Consortium provides these study vaccines, developed by researchers at Scripps Research, for the study for HIV/AIDS Vaccine Development (CHAVD).
These study vaccines are manufactured using mRNA technology, a piece of genetic code carried into your body by the vaccine as a message with instructions. The mRNA technology was developed by Moderna for the COVID-19 vaccine, which instructs the body’s cells to make the SARS-CoV-2 spike protein. Instead of showing the immune system pieces of HIV, the study vaccines carry instructions that show human muscle cells how to make small pieces that resemble parts of HIV but are not actual pieces of the virus. Therefore, participants cannot get HIV from the vaccines.
When people get a vaccine injection in the muscle of their arm, the cells in that muscle will get the instructions and start to make the different types of HIV pieces and display these pieces on the surface of the muscle cell. The immune system will then be able to see these HIV pieces and learn how to recognize them.
Researchers hope that the immune system will respond by making antibodies and T-cells that could fight HIV if a person is ever exposed to the virus in the future.
The mRNA instructions do their work in the part of the muscle cell called the cytoplasm and only remain in the body for a couple of days before they break down naturally. The mRNA does not enter the nucleus of the cells, which is where human DNA is located. Therefore, the mRNA cannot interact with human DNA.
The study vaccines have not been given to people before. Prior research in animals was promising and found to be safe. The HVTN 302 trial is conducted in a way in which safety is carefully monitored.
The process is simple: participants indicate that they are interested, they complete an online screener, and staff contact them to complete a pre-screen over the phone. They then schedule their first study visit, where the participant receives more information on the study, signs consent forms and undergoes a physical exam. After that, if the participant is approved for the study, they are scheduled for their first vaccination.
Columbia Research Unit and Project ACHIEVE are appealing to community members to screen for and join the HVTN 302 trial. As with recent advances in the COVID-19 vaccine development, study participants are essential in furthering the science. Tens of thousands of people have participated in the studies that led to the development of the lifesaving COVID-19 vaccines. As with the COVID-19 vaccine trials, Project ACHIEVE and Columbia University highly encourage those from racial, ethnic, and sexual minority communities to participate in the study, as a diverse pool of participants is essential in the success of the study. To learn more about the study or complete the eligibility screener, community members can visit www.JoinUsNYC.org or contact us at:
Phone: (212) 388-0008
E-mail: [email protected]
Phone/Text: (347) 770-2201
E-mail: [email protected]
Research sites are recruiting HIV-negative community members to join the global effort to create an effective HIV preventive vaccine.
About New York Blood Center: Founded in 1964, New York Blood Center (NYBC) is a nonprofit organization that is one of the largest independent, community-based blood centers in the world. NYBC, along with its operating divisions Community Blood Center of Kansas City, Missouri (CBC), Innovative Blood Resources (IBR), Blood Bank of Delmarva (BBD), and Rhode Island Blood Center (RIBC), collect approximately 4,000 units of blood products each day and serve local communities of more than 75 million people in the Tri-State area (NY, NJ, CT), Mid Atlantic area (PA, DE, MD, VA), Missouri and Kansas, Minnesota, Nebraska, Rhode Island, and Southern New England. NYBC and its operating divisions also provide a wide array of transfusion-related medical services to over 500 hospitals nationally, including Comprehensive Cell Solutions, the National Center for Blood Group Genomics, the National Cord Blood Program, and the Lindsley F. Kimball Research Institute, which — among other milestones — developed a practical screening method for hepatitis B as well as a safe, effective and affordable vaccine, and a patented solvent detergent plasma process innovating blood-purification technology worldwide.
About The Division of Infectious Diseases at Columbia University Irving Medical Center (CUIMC): The Division of Infectious Diseases at Columbia University Irving Medical Center (CUIMC) is devoted to excellence in patient care, community health, biomedical research, and teaching, and to developing the next generation of leaders in academic medicine and public health. Located in upper Manhattan and affiliated with New York-Presbyterian Hospital, the division delivers multidisciplinary HIV and Hepatitis C treatment and prevention care, in addition to providing general infectious diseases and transplant infectious disease care to diverse communities of patients.
The NIH-funded Columbia Research Unit in the Division of Infectious Diseases has been advancing the science of HIV treatment and prevention and emerging infections like SARS-CoV-2 by conducting studies on novel drug development, optimization of antiretroviral therapy, HIV and COVID-19 translational science, and HIV and COVID-19 vaccine safety and efficacy. The division also supports active research in health disparities and health outcomes, bacterial pathogenesis, transplant immunology, molecular epidemiology, health care epidemiology, and antimicrobial resistance. Close relationships with other divisions, departments, and colleges within Columbia University further facilitate research and training opportunities both domestically and internationally.